Status and phase
Conditions
Treatments
About
This is a phase 1b, dose escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and efficacy of JMKX001899 in combination with IN10018 or in combination with chemotherapy or in combination with IN10018 and chemotherapy in subjects with locally advanced or metastatic NSCLC with KRAS G12C mutation.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
72 participants in 3 patient groups
Loading...
Central trial contact
Jieting Zhao
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal